Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Pierre Fabre

Evaluate

Thumbnail
May 13, 2019

Disappointing Nerlynx sales shows Pierre Fabre timing is everything

Thumbnail
April 01, 2019

Puma prompts disappointment with European Nerlynx deal

Article image
Vantage logo
February 22, 2019

Upcoming events – Beacons of hope for Array and Proteon

Array Biopharma hopes for a label extension for its Braf/Mek inhibitor, and Proteon tries to make a better fist of its second phase III trial of vonapanitase.

Article image
Vantage logo
January 31, 2019

In sticking to the knitting has Array given up too much?

At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.

Vantage logo
March 20, 2017

Binimetinib withdrawal reveals Array of issues

Vantage logo
February 20, 2017

Tersera gives Zoladex a life after death

Vantage logo
June 05, 2016

Asco 2016 – Array to test Braf/Mek combo in colorectal cancer

Vantage logo
November 24, 2015

Astra gives as well as taking away

Vantage logo
February 20, 2014

Mid-cap consolidation spree looks set to yield bigger deals

Vantage logo
July 27, 2010

EP Vantage Interview - Cerenis adds €40m to the HDL debate

Vantage logo
June 23, 2010

Is Cypress backing the wrong horse?

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up